Mapping of the Antibody and T Cell Recognition Profiles of the H_N Domain (Residues 449–859) of the Heavy Chain of Botulinum Neurotoxin A in Two High-Responder Mouse Strains

References

• Atassi, M Z. (1984). Antigenic structures of proteins. Their determination has revealed important aspects of immune recognition and generated strategies for synthetic mimicking of protein binding sites. Eur. J. Biochem. 145:1–20., [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Atassi, M Z. (2004). Basic immunological aspects of botulinum toxin therapy. Mov. Disord. 19(Suppl. 8):S68–S84. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Atassi, M Z., Bixler, G S. (1988). Comparison of the submolecular recognition of proteins by T and B cells. In: Kohler, H., LoVerde, P T., eds. Vaccines: New Concepts and Developments. Essex: Longman Scientific and Technical, pp. 58–70.
   Google Scholar
• Atassi, M Z., Dolimbek, B Z. (1995). Regions of interactions between nicotinic acetylcholine receptor and α-neurotoxins and development of a synthetic vaccine against toxin poisoning. In: Atassi, M Z., Appella, E., eds. Methods of Protein Structure Analysis. New York: Plenum, pp. 311–326.
   Google Scholar
• Atassi, M Z., Dolimbek, B Z. (2004). Mapping of the antibody-binding profile on botulinum neurotoxin A HN-domain (residues 449–859) with anti-toxin antibodies from four host species. Full profile of the continuous antigenic regions of the H-chain of botulinum neurotoxin A. Protein J. 23:39–52. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Atassi, M Z., Oshima, M. (1999). Structure, activity, and immune (T and B cell) recognition of botulinum neurotoxins. Crit. Rev. Immunol. 19:219–260. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Atassi, M Z., Yoshioka, M., Bean, M., Bixler, G S. (1987). Non-specific peptide size effects in the recognition by site-specific T-cell clones. Demonstration with a T site of myoglobin. Biochem. J. 246:307–312. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Atassi, M Z., Torres, J V., Wyde, P R. (1989). Cytotoxic and helper T-lymphocyte responses to antibody recognition regions on influenza virus hemagglutinin. Adv. Exp. Med. Biol. 251:49–63. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Atassi, M Z., Dolimbek, B Z., Hayakari, M., Middlebrook, J L., Whitney, B., Oshima, M. (1996). Mapping of antibody binding regions on botulinum neurotoxin H-chain domain 855–1296 with anti toxin antibodies from three host species. J. Prot. Chem. 15:691–700. [CSA]
   PubMedGoogle Scholar
• Becker-Wegerich, P., Rauch, L., Ruzicka, T. (2001). Botulinum toxin A in the therapy of mimic facial lines. Clin. Exp. Dermatol. 26:619–630. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   Google Scholar
• Berardelli, A., Abbruzzese, G., Bertolasi, L., Cantarella, G., Carella, F., Curra, A., De Grandis, D., DeFazio, G., Galardi, G., Girlanda, P., Livrea, P., Modugno, N., Priori, A., Ruoppolo, G L., Vacca, L., Manfredi, M. (1997). Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology. Ital. J. Neurol. Sci. 18:261–269. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Binder, W J., Brin, M F., Blitzer, A., Pogoda, J M. (2002). Botulinum toxin type A (BOTOX) for treatment of migraine. Dis. Mon. 48:323–335. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bixler, G S., Atassi, M Z. (1983). Molecular localization of the full profile of the continuous regions recognized by myoglobin-primed T-cells using synthetic overlapping peptides encompassing the entire molecule. Immunol. Commun. 12:593–603. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Bixler, G S., Atassi, M Z. (1984). T cell recognition of myoglobin. Localization of the sites stimulating T cell proliferative responses by synthetic overlapping peptides encompassing the entire molecule. J. Immunogenet. 11:339–353. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Bixler, G S., Bean, M., Atassi, M Z. (1986). Site recognition by protein-primed T cells shows a non-specific peptide size requirement beyond the essential residues of the site. Demonstration by defining an immunodominant T site in myoglobin. Biochem. J. 240:139–146. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Blasi, J., Binz, T., Yamasaki, S., Link, E., Niemann, H., Jahn, R. (1994). Inhibition ofneurotransmitter release by clostridial neurotoxins correlates with specific proteolysis of synaptosomal proteins. J. Physiol. (Paris) 88:235–241. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Borodic, G E., Acquadro, M., Johnson, E A. (2001). Botulinum toxin therapy for pain and inflammatory disorders: mechanisms and therapeutic effects. Exp. Opin. Investig. Drugs 10:1531–1544. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Brett, S J., Blau, J., Hughes-Jenkins, C M., Rhodes, J., Liew, F Y., Tite, J P. (1991). Human T cell recognition of influenza A nucleoprotein. Specificity and genetic restriction of immunodominant T helper cell epitopes. J. Immunol. 147:984–991. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Burgen, A S. V., Dickens, F., Zatman, L J. (1949). The action of botulinum toxin on the neuro-muscular junction. J. Physiol. (Lond.) 109:10–24.
   Google Scholar
• Cardoso, F., Jankovic, J. (1995). Clinical use of botulinum neurotoxins. Curr. Top. Microbiol. Immunol. 195:123–141. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Chicz, R M., Urban, R G., Gorga, J C., Vignali, D A., Lane, W S., Strominger, J L. (1993). Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27–47. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Das Gupta, B R. (1989). The structure of botulinum neurotoxin. In: Simpson, L L. ed.,Botulinum Neurotoxins and Tetanus Toxin. New York: Academic, pp. 53–67.
   Google Scholar
• Das Gupta, B R., Sugiyama, H. (1972). A common subunit structure in Clostridium botulinum type A, B and E toxins. Biochem. Biophys. Res. Commun. 48:108–112. [CROSSREF]
   PubMed Web of Science ®Google Scholar
• David, C S., Atassi, M Z. (1982). Genetic control and intersite influences on the immune response to sperm whale myoglobin. Adv. Exp. Med. 150:97–125.
   PubMed Web of Science ®Google Scholar
• Demotz, S., Lanzavecchia, A., Eisel, U., Niemann, H., Widmann, H., Corradin, G. (1989). Delineation of several DR-restricted tetanus toxin T cell epitopes. J. Immunol. 142:394–402. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Dolimbek, B Z., Atassi, M Z. (1994). α-Bungarotoxin peptides afford a synthetic vaccine against toxin poisoning. J. Prot. Chem. 13:490–493.
   Google Scholar
• Dolimbek, B Z., Atassi, M Z. (1996). Protection against α-bungarotoxin poisoning by immunization with synthetic toxin peptides. Mol. Immunol. 33:681–689. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Foran, P G., Mohammed, N., Lisk, G O., Nagwaney, S., Lawrence, G W., Johnson, E., Smith, L., Aoki, K R., Dolly, J O. (2003). Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, E, and F compared with the long lasting type A. Basis for distinct durations of inhibition of exocytosis in central neurons. J. Biol. Chem. 278:1363–1371. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gammon, G., Klotz, J., Ando, D., Sercarz, E E. (1990). The T cell repertoire to a multideterminant antigen. Clonal heterogeneity of the T cell response, variation between syngeneic individuals, and in vitro selection of T cell specificities. J. Immunol. 144:1571–1577. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Göschel, H., Wohlfarth, K., Frevert, J., Dengler, R., Bigalke, H. (1997). Botulinum A toxin therapy: neutralizing and nonneutralizing antibodies-therapeutic consequences. Exp. Neurol. 147:96–102. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gui, D., Rossi, S., Runfola, M., Magalini, S C. (2003). Review article: botulinum toxin in the therapy of gastrointestinal motility disorders. Aliment. Pharmacol. Ther. 18:1–16. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Gundersen, CB. (1980). The effects of botulinum toxin on the synthesis, storage and release of acetylcholine. Prog. Neurobiol. 14:99–119., [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Hunter, W M., Greenwood, F C. (1962). Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature (Lond.) 194:495–496.
   PubMed Web of Science ®Google Scholar
• Jankovic, J. (2002). Botulinum toxin: clinical implications of antigenicity and immunoresistance. In: Brin, M F., Hallett, M., Jankovic, J., eds. Scientific and Therapeutic Aspects of Botulinum Toxin. Philadelphia, PA: Lippincott Williams & Wilkins, pp. 409–416.
   Google Scholar
• Kazim, A L., Atassi, M Z. (1980). A novel and comprehensive synthetic approach for the elucidation of protein antigenic structures. Determination of the full antigenic profile of the alpha-chain of human haemoglobin. Biochem. J. 191:261–264. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Kazim, A L., Atassi, M Z. (1982). Structurally inherent antigenic sites. Localization of the antigenic sites of the alpha-chain of human haemoglobin in three host species by a comprehensive synthetic approach. Biochem. J. 203:201–208. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Koriazova, L K., Montal, M. (2003). Translocation of botulinum neurotoxin light chain protease through the heavy chain channel. Nat. Struct. Biol. 10:13–18. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Kozaki, S., Togashi, S., Sakaguchi, G. (1981). Separation of Clostridium botulinum type A derivative toxin into two fragments. Jpn. J. Med. Sci. Biol. 34:61–68. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar
• Lacy, D B., Tepp, W., Cohen, A C., DasGupta, B R., Stevens, R C. (1998). Crystal structure of botulinum neurotoxin type A and implications for toxicity. Nat. Struct. Biol. 5:898–902. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Meloen, R H., Casal, J I., Dalsgaard, K., Langeveld, J P.M. (1995). Synthetic peptide vaccines: success at last. Vaccine 13:885–886. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Meunier, F A., Schiavo, G., Molgo, J. (2002). Botulinum neurotoxins: from paralysis to recovery of functional neuromuscular transmission. J. Physiol. (Paris) 96:105–113. [CSA], [CROSSREF]
   PubMedGoogle Scholar
• Meunier, F A., Lisk, G., Sesardic, D., Dolly, J O. (2003). Dynamics of motor nerve terminal remodeling unveiled using SNARE-cleaving botulinum toxins: the extent and duration are dictated by the sites of SNAP-25 truncation. Mol. Cell. Neurosci. 22:454–466. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Middlebrook, J L. (1995). Protection strategies against botulinum toxin. Adv. Exp. Med. Biol. 383:93–98. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Miyazaki, S., Iwasaki, M., Sakaguchi, G. (1977). Clostridium botulinum type D toxin: purification, molecular structure, and some immunological properties. Infect. Immun. 17:395–401. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Montecucco, C., Schiavo, G. (1995). Structure and function of tetanus and botulinum neurotoxins. Q. Rev. Biohys. 28:423–472.
   PubMed Web of Science ®Google Scholar
• Okuda, K., Christadoss, P R., Twining, S S., Atassi, M Z., David, C S. (1978). Genetic control of immune response to sperm whale myoglobin in mice. I. T lymphocyte proliferative response under H-2-linked Ir gene control. J. Immunol. 121:866–868. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Okuda, K., Twining, S S., David, C S., Atassi, M Z. (1979). Genetic control of immune response to sperm whale myoglobin in mice. II. T lymphocyte proliferative response to the synthetic antigenic sites. J. Immunol. 123:182–188. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Oshima, M., Hayakari, M., Middlebrook, J L., Atassi, M Z. (1997). Immune recognition of botulinum neurotoxin type A: regions recognized by T cells and antibodies against the protective H(C) fragment (residues 855–1296) of the toxin. Mol. Immunol. 34:1031–1040., [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Oshima, M., Middlebrook, J L., Atassi, M Z. (1998). Antibodies and T cells against synthetic peptides of the C-terminal domain (Hc) of botulinum neurotoxin type A and their cross-reaction with Hc. Immunol. Lett. 60:7–12. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Payling-Wright, G. (1955). The neurotoxins of Clostridium botulinum and Clostridium tetani. Pharmacol. Rev. 7:413–465.
   PubMed Web of Science ®Google Scholar
• Rosenberg, J S., Middlebrook, J L., Atassi, M Z. (1997). Localization of the regions on the C-terminal domain of the heavy chain of botulinum A recognized by T lymphocytes and by antibodies after immunization of mice with pentavalent toxoid. Immunol. Invest. 26:491–504. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Sakaguchi, G., Ohishi, I., Kozaki, S. (1988). Botulism—structure and chemistry of botulinum. In: Hardgree, M C., Tu, A T., eds. Handbook of Natural Toxins. New York: Marcel Dekker, pp. 191–216.
   Google Scholar
• Schiavo, G., Poulain, B., Rossetto, O., Benfenati, F., Tauc, L., Montecucco, C. (1992a). Tetanus toxin is a zinc protein and its inhibition of neurotransmitter release and protease activity depend on zinc. EMBO J. 11:3577–3583. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Schiavo, G., Rossetto, O., Santucci, A., DasGupta, B R., Montecucco, C. (1992b). Botulinum neurotoxins are zinc proteins. J. Biol. Chem. 267:23479–23483. [PUBMED], [INFOTRIEVE]
   PubMed Web of Science ®Google Scholar
• Silberstein, S D. (2001). Review of botulinum toxin type A and its clinical applications in migraine headache. Exp. Opin. Pharmacother. 10:1649–1654. [CROSSREF]
   Google Scholar
• Simeckova-Rosenberg, J., Yun, Z., Wyde, P R., Atassi, M Z. (1995). Protection of mice against lethal viral infection by synthetic peptides corresponding to B- and T-cell recognition sites of influenza A hemagglutinin. Vaccine 13:927–932. [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Simpson, L L. (1989). Peripheral actions of the botulinum toxins. In: Simpson, L L., ed. Botulinum Neurotoxin and Tetanus Toxin. New York: Academic Press, pp. 153–178.
   Google Scholar
• Swaminathan, S., Eswaramoorthy, S. (2000). Structural analysis of the catalytic and binding sites of Clostridium botulinum neurotoxin B. Nat. Struct. Biol. 7:693–699. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Turton, K., Chaddock, J A., Acharya, K R. (2002). Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem. Sci. 27:552–558. [PUBMED], [INFOTRIEVE], [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Twining, S S., David, C S., Atassi, M Z. (1981). Genetic control of the immune response to myoglobin. IV. Mouse antibodies in outbred and congenic strains against sperm-whale myoglobin recognize the same antigenic sites that are recognized by antibodies raised in other species. Mol. Immunol. 18:447–450. [PUBMED], [INFOTRIEVE], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Young, C R., Atassi, M Z. (1982). Dissection of the molecular parameters for T-cell recognition of a myoglobin antigenic site. Adv. Exp. Med. Biol. 150:79–93.
   Web of Science ®Google Scholar
• Young, C R., Atassi, M Z. (1983). T-lymphocyte recognition of sperm-whale myoglobin. Responses of T-cells from mouse strains primed with synthetic peptide carrying antigenic site 5 and relation to antigen presentation. J. Immunogenet. 10:151–160. [PUBMED], [INFOTRIEVE], [CSA]
   PubMedGoogle Scholar
• Yang, K H., Sugiyama, H. (1975). Purification and properties of Clostridium botulinum type F toxin. Appl. Microbiol. 29:598–603. [PUBMED], [INFOTRIEVE]
   PubMedGoogle Scholar